In this study, a gene delivery method utilizing chitosan-PLGA was developed to deliver the tumor suppressor miR29A-B1 and miR34A, along with CASP8, for NSCLC therapy. This evidence concerns the gene CASP8 and non-small cell lung carcinoma.